Metastatic Osteosarcoma Treatment Market Is Expected to Grow Rapidly With Innova Therapeutics Inc. Receiving the U.S. FDA Rare Pediatric Disease Designation for IVT-8086 Indicated for the Treatment of Osteosarcoma

 

Metastatic Osteosarcoma Treatment

Metastatic osteosarcoma is one form of the disease osteoarthritis. It has been found that this disease occurs due to a problem with the cells in the spinal cord that are responsible for the proper function of the joints. The disease generally affects the aging group and those individuals suffering from other medical conditions like diabetes etc. The pain caused due to metastatic osteosarcoma can be so severe that it leads to tremendous disability to the affected person.

Increasing drug pipeline for malignant bones and soft tissue cancer is expected to drive growth of the global metastatic osteosarcoma treatment market. Key biopharmaceutical and pharmaceutical companies are focused on research and development activities to synthesize novel drug treatment for soft tissue and malignant bone cancer. For instance, in September 2020, Junshi Biosciences, a major biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) Orphan Drug designation to Toripalimab for the treatment of soft tissue sarcoma. Furthermore, in January 2020, Epizyme, a U.S.-based biopharmaceutical company, received the U.S. FDA approval for Tazverik indicated for the treatment of a rare type of soft tissue sarcoma that's spread and can't be treated with surgery. Hence, these factors are expected to drive growth of the global metastatic osteosarcoma treatment market. Furthermore, growing government initiatives to raise awareness regarding bone cancer is expected to propel the global metastatic osteosarcoma treatment market growth in the near future.

High costs associated with cancer therapies coupled with the presence of alternative therapies such as new forms of radiation therapy are expected to hamper the global metastatic osteosarcoma treatment market growth in the near future. Besides, stringent approval policies are expected to restrain growth of the market. Among regions, North America is expected to witness significant growth in the global metastatic osteosarcoma treatment market. This is owing to a high prevalence of metastatic osteosarcoma in the region. According to the American Cancer Society (ASC), around 1,000 new cases of osteosarcoma are diagnosed in the U.S. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to improving healthcare infrastructure in the region.

Key players involved in the global metastatic osteosarcoma treatment market are Luitpold Pharmaceuticals Inc., Mylan Laboratories Limited, Dr. Reddy’s Laboratories Ltd., Alvogen Inc., Sun Pharmaceutical Industries Ltd., Gland Pharma Limited, Innova Therapeutics Inc., and Sagent Pharmaceuticals Inc.

For instance, in October 2020, Innova Therapeutics Inc., a biotechnology company, received the U.S. FDA rare pediatric disease designation for IVT-8086 indicated for the treatment of osteosarcoma.